42
Participants
Start Date
July 31, 2008
Primary Completion Date
December 31, 2012
Study Completion Date
December 31, 2013
Sipuleucel-T with Booster
Sipuleucel-T is an autologous active cellular immunotherapy product designed to stimulate an immune response against prostate cancer. Sipuleucel-T consists of autologous peripheral blood mononuclear cells (PBMCs), including antigen presenting cells (APCs), that have been activated in vitro with a recombinant fusion protein.
Sipuleucel-T without Booster
Sipuleucel-T is an autologous active cellular immunotherapy product designed to stimulate an immune response against prostate cancer. Sipuleucel-T consists of autologous peripheral blood mononuclear cells (PBMCs), including antigen presenting cells (APCs), that have been activated in vitro with a recombinant fusion protein.
University of Utah School of Medicine, Salt Lake City
USC / Norris Comprehensive Cancer Center, Los Angeles
UCSF Comprehensive Cancer Center, San Francisco
Kaiser Permanente Portland, Portland
Oregon Health & Science University, Portland
Virginia Mason Medical Center, Seattle
Seattle Cancer Care Alliance, Seattle
Lead Sponsor
University of California, San Francisco
OTHER
Dendreon
INDUSTRY